Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MRCKβ CRISPR/Cas9 KO Plasmid (h): sc-403169
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MRCKβ CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MRCKβ genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MRCKβ Antibody (C-12): sc-374597
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MRCKβ CRISPR/Cas9 KO Plasmid (h) | sc-403169 | 20 µg | $397.00 |
Overview
CDC42BPB encodes MRCKβ (myotonic dystrophy kinase-related Cdc42-binding kinase beta), a serine/threonine kinase that acts downstream of the Rho GTPase CDC42 to coordinate actin–myosin contractility. MRCKβ phosphorylates cytoskeletal regulators including myosin light chain and influences cell polarity, lamellipodia formation, and directional migration through Rho/ROCK-related signaling networks. These activities connect CDC42BPB to pathways governing adhesion dynamics, morphogenesis, and vesicle trafficking, processes frequently perturbed in invasive and metastatic phenotypes. Altered MRCKβ signaling has been studied in the context of tumor cell motility and other disorders involving cytoskeletal dysregulation.
MRCKβ CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CDC42BPB gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CDC42BPB together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CDC42BPB open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MRCKβ protein expression.
This CRISPR knockout system enables efficient generation of CDC42BPB-deficient cell models for investigation of MRCKβ signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CDC42BPB exon(s) critical for MRCKβ function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CDC42BPB genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MRCKβ CRISPR/Cas9 KO Plasmid (h) and MRCKβ CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CDC42BPB locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MRCKβ HDR Plasmid (h) and MRCKβ HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CDC42BPB homology arms to support homology-directed repair at defined CDC42BPB target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.